Amar U. Kishan, MD

Amar Kishan, MD

Professor, Department of Radiation Oncology




Radiation Oncology

Institutional Affiliation

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica



Transitional, Scripps Mercy Hospital, 2012 - 2013


MD, Harvard Medical School, 2012


Radiation Oncology, UCLA School of Medicine, 2013 - 2017

Board Certification

Radiation Oncology, American Board of Radiology, 2018

Contact Information

Scientific Interests

Dr. Amar Kishan is interested in optimizing the treatment of genitourinary malignancies, particularly prostate cancers and the use of advanced radiation techniques in this setting. He is also interested in the malignancies of the head and neck and central nervous system.

Highlighted Publications

Wang C, Kishan AU, Kamrava M, Steinberg ML, King CR. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1045-1052. doi: 10.1016/j.ijrobp.2017.03.040. Epub 2017 Mar 31.

Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 May;71(5):766-773. doi: 10.1016/j.eururo.2016.06.046. Epub 2016 Jul 21.

Kishan AU, Wang PC, Sharif J, Kupelian PA, Steinberg ML, McCloskey SA. Clinical Indicators of Psychosocial Distress Predict for Acute Radiation-Induced Fatigue in Patients Receiving Adjuvant Radiation Therapy for Breast Cancer: An Analysis of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):946-955. doi: 10.1016/j.ijrobp.2016.01.062. Epub 2016 Feb 11.

Kishan AU, Wang PC, Upadhyaya SK, Hauswald H, Demanes DJ, Nickols NG, Kamrava M, Sadeghi A, Kupelian PA, Steinberg ML, Prionas ND, Buyyounouski MK, King CR. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Pract Radiat Oncol. 2016 Jul-Aug;6(4):268-75. doi: 10.1016/j.prro.2015.11.002. Epub 2015 Nov 10.

Kishan AU, Lamb JM, Jani SS, Kang JJ, Steinberg ML, King CR. Pelvic nodal dosing with registration to the prostate: implications for high-risk prostate cancer patients receiving stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):832-9. doi: 10.1016/j.ijrobp.2014.11.035.